EFSA/ECHA (2018) guidance for the identification of endocrine disruptors (ED): looking back after the first 3 years of implementation

News from ECHA’s Committee for Risk Assessment (RAC) – Adoption of Opinion on Harmonised Classification and Labelling for MWCNTs

For hazards of highest concern (e.g., carcinogenicity, mutagenicity, reproductive toxicity), the European harmonised classification and labelling (CLH) system is set […]

Next generation risk assessment (NGRA) for skin sensitisation: Case studies with resorcinol and propyl paraben

Skin sensitisation is one of the key adverse health effects to be addressed in the safety assessment of cosmetic ingredients. […]

Initial reflections on a way forward to update the REACH Annexes in relation to endocrine disruption properties – OPEN FOR FEEDBACK UNTIL 16 NOVEMBER

The European Commission is looking for comments on its intention to update REACH data requirements for identifying and assessing endocrine […]

Implementing Regulation (EU/2020/1435) on the duties placed on registrants to update their registrations along with proposed deadlines under the EU REACH Regulation

Article 22(1) of Regulation (EC) No 1907/2006 (REACH regulation) places a responsibility on registrants (whether individual registrants or the lead […]